
Kidswell Bio Corporation (KWB), formerly known as Gene Techno Science, has been growing by leveraging our expertise in Biosimilar field in Japan. By 2024, four BS products were brought to market by our partner pharmaceutical companies as outcomes of co-developments between the companies and KWB. Besides, KWB has engaged in research and development for regenerative medicine with stem cells from human exfoliated deciduous teeth (SHED) since 2019, which targeted pediatric diseases, orphan disease and intractable disease with the aim of achieving comprehensive healthcare solutions for patients suffering from these diseases as well as for their families and caregivers. 
On the 1st of April 2024, the regenerative medicine business became independent as S-Quatre Corporation (SQ). KWB and SQ lead biosimilar business and regenerative medicine business　respectively, and grow together as two pillars of Kidswell Bio group.

キッズウェル・バイオ株式会社(旧株式会社ジーンテクノサイエンス)はバイオシミラー医薬品事業により成長してきた。パートナー製薬企業との共同開発の結果、2024年までに4つのバイオシミラー製品を日本にて上市させている。一方で、2019年からは、乳歯由来歯髄幹細胞を用いた再生医療の研究開発に着手し、希少疾患、難病に加えて、小児疾患を重点的なターゲットと定め、患者様、及びそのご家族や介護者の方を含めた包括的なケアを目指した研究開発を行なってきた。KWBは2024年4月1日にこの再生医療事業を専門に行なう子会社である株式会社S-Quatreを設立し、現在はキッズウェル・バイオグループとしてバイオシミラーと再生医療の両事業を展開している。

Kidswell Bio Corporation

Org chart

Teams

Offices

Similar companies